• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Murray on real-world study of antegrade administration of reverse thermal mitomycin gel for UTUC

Video

Katie Murray, DO, urologic oncologist and assistant professor of Urology at the University of Missouri, discusses findings from a real-world study of antegrade administration of reverse thermal mitomycin gel (Jelmyto) for primary chemoablation of upper tract urothelial carcinoma via percutaneous nephrostomy tube. The study, which was presented at the 2022 AUA Annual Meeting (abstract PD58-06), sought to analyze whether antegrade administration of Jelmyto might decrease some of the comorbidity and complications reported in the pivotal OLYMPUS trial that led to the FDA approval of the treatment.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.